Clinical Trial Update: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification [Phase 3]

View source ↗

Summary

Phase 3 trial update on Savolitinib in combination with Osimertinib for advanced non-small cell lung cancer with MET amplification; the study is currently not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Savolitinib (savolitinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING